Original articles
Shuhua Shan, Jinping Niu, Ruopeng Yin, Jiangying Shi, Lizhen Zhang, Caihong Wu, Hanqing Li, Zhuoyu Li. Peroxidase from foxtail millet bran exerts anti-colorectal cancer activity via targeting cell-surface GRP78 to inactivate STAT3 pathway[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1254-1270

Peroxidase from foxtail millet bran exerts anti-colorectal cancer activity via targeting cell-surface GRP78 to inactivate STAT3 pathway
Shuhua Shana, Jinping Niua, Ruopeng Yina, Jiangying Shia, Lizhen Zhangb, Caihong Wua, Hanqing Lib, Zhuoyu Lia,b
a. Institute of Biotechnology, Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Shanxi University, Taiyuan 030006, China;
b. School of Life Science, Shanxi University, Taiyuan 030006, China
Abstract:
Molecular targeted therapy has become an emerging promising strategy in cancer treatment, and screening the agents targeting at cancer cell specific targets is very desirable for cancer treatment. Our previous study firstly found that a secretory peroxidase of class III derived from foxtail millet bran (FMBP) exhibited excellent targeting anti-colorectal cancer (CRC) activity in vivo and in vitro, whereas its underlying target remains unclear. The highlight of present study focuses on the finding that cell surface glucose-regulated protein 78 (csGRP78) abnormally located on CRC is positively correlated with the anti-CRC effects of FMBP, indicating it serves as a potential target of FMBP against CRC. Further, we demonstrated that the combination of FMBP with the nucleotide binding domain (NBD) of csGRP78 interfered with the downstream activation of signal transducer and activator of transcription 3 (STAT3) in CRC cells, thus promoting the intracellular accumulation of reactive oxygen species (ROS) and cell grown inhibition. These phenomena were further confirmed in nude mice tumor model. Collectively, our study highlights csGRP78 acts as an underlying target of FMBP against CRC, uncovering the clinical potential of FMBP as a targeted agent for CRC in the future.
Key words:    Foxtail millet bran    FMBP    csGRP78    STAT3    ROS    Colorectal cancer   
Received: 2021-06-10     Revised: 2021-08-31
DOI: 10.1016/j.apsb.2021.10.004
Funds: This study was supported by National Natural Science Foundation of China (Nos. 31500630, 31770382, 32072220, and 81803238); "1331 Project" Key Innovation Center and Team, National Key Research and Development Project (No. 2020YFD1001405, China); Shanxi Key Laboratory for Research and Development of Regional Plants, Higher Education Institution Project of Shanxi Province:Ecological Remediation of Soil Pollution Disciplines Group (No. 20181401, China); the Open Project Program of Xinghuacun College of Shanxi University[Shanxi Institute of Brewing Technology and Industry (Preparation)] (No. XCSXU-KF-202004, China).
Corresponding author: Zhuoyu Li,E-mai:lzy@sxu.edu.cn     Email:lzy@sxu.edu.cn
Author description:
Service
PDF(KB) Free
Print
0
Authors
Shuhua Shan
Jinping Niu
Ruopeng Yin
Jiangying Shi
Lizhen Zhang
Caihong Wu
Hanqing Li
Zhuoyu Li

References:
[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68: 394-24
[2] Wei QY, Xu YM, Lau ATY. Recent progress of nanocarrier-based therapy for solid malignancies. Cancers 2020;12: 2783
[3] Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol 2018;834: 188-196
[4] Ingham M, Schwartz GK. Cell-cycle therapeutics come of age. J Clinical Oncol 2017;35: 2949-2959
[5] Reddy PS, Lokhande KB, Nagar S, Reddy VD, Murthy PS, Swamy KV. Molecular modeling, docking, dynamics and simulation of gefitinib and its derivatives with EGFR in non-small cell lung cancer. Curr Comput Aided Drug Des 2018;14: 246-252
[6] Augustine T, Maitra R, Zhang J, Nayak J, Goel S. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. Invest New Drugs 2019;37: 948-960
[7] Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer 2017;8: 410-416
[8] Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011;434: 181-188
[9] Lee, A. S. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 2014;14: 263-276
[10] Li Z, Zhang L, Zhao Y, Li H, Xiao H, Fu R. et al. Cell-surface GRP78 facilitates colorectal cancer cell migration and invasion. Int J Biochem Cell Biol 2013;45: 987-994
[11] Gonzalez-Gronow M, Pizzo, SV, Misra UK. GRP78 (BiP): a multifunctional cell surface receptor. In: Henderson B., Pockley A, editors. Cellular trafficking of cell stress proteins in health and disease. Dordrecht: Springer Netherlands; 2012. p.229-242
[12] Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004;6: 275-284
[13] Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, et al. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res 2013;19: 6802-6811
[14] McFarland BC, Stewart J Jr, Hamza A, Nordal R, Davidson DJ, Henkin J, et al. Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1. Cancer Res 2009;69: 5537-5545
[15] Burikhanov R, Zhao Y, Goswami A, Qiu S, Rangnekar, VM. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 2009;138: 377-388
[16] Zhang L, Li Z, Shi T, La X, Li H, Li Z. Design, purification and assessment of GRP78 binding peptide-linked subunit A of subtilase cytotoxic for targeting cancer cells. BMC Biotechnol 2016;16: 65
[17] Wang Y, Wu H, Li Z, Yang P, Li Z. A positive feedback loop between GRP78 and VPS34 is critical for GRP78-mediated autophagy in cancer cells. Exp Cell Res 2017;351: 24-35
[18] Li Z, Zhao C, Li Z, Zhao Y, Shan S, Shi T, et al. Reconstructed mung bean trypsin inhibitor targeting cell surface GRP78 induces apoptosis and inhibits tumor growth in colorectal cancer. Int J Biochem Cell Biol 2014;47: 68-75
[19] Shan S, Li Z, Newton IP, Zhao C, Li Z, Guo M. A novel protein extracted from foxtail millet bran displays anti-carcinogenic effects in human colon cancer cells. Toxicol Lett 2014; 227:129-138
[20] Shan S, Li Z, Guo S, Li Z, Shi T, Shi J. A millet bran-derived peroxidase inhibits cell migration by antagonizing STAT3-mediated epithelial-mesenchymal transition in human colon cancer. J Funct Foods 2014;10: 444-455
[21] Shan S, Wu C, Shi J, Zhang X, Niu J, Li H, et al. Inhibitory effects of peroxidase from Foxtail Millet Bran on colitis-associated colorectal carcinogenesis by the blockade of glycerophospholipid metabolism. J Agric Food Chem 2020;68: 8295-8307
[22] Shan S, Shi J, Li Z, Gao H, Shi T, Li Z, et al. Targeted anti-colon cancer activities of a millet bran-derived peroxidase were mediated by elevated ROS generation. Food Funct 2015;6: 2331-2338
[23] La X, Zhang L, Li H, Li Z, Song G, Yang P, et al. Ajuba receptor mediates the internalization of tumor-secreted GRP78 into macrophages through different endocytosis pathways. Oncotarget 2018;9: 15464-15479
[24] Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013;341: 84-87
[25] Notaro A, Sabella S, Pellerito O, Di Fiore R, De Blasio A, Vento R, et al. Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis. Int J Biol Sci 2014;10: 466-478
[26] Devitt G, Thomas M, Klibanov AM, Pfeiffer T, Bosch V. Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine. J Virol Methods 2007;146: 298-304
[27] Zhang L, Li Z, Ding G, La X, Yang P, Li Z. GRP78 plays an integral role in tumor cell inflammation-related migration induced by M2 macrophages. Cell Signal 2017;37: 136-148
[28] Kang JM, Park S, Kim SJ, Hong HY, Jeong J, Kim HS, et al. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-β signaling. Oncogene 2012;31: 5123-5131
[29] Chang J, Kim Y, Kwon HJ. Advances in identification and validation of protein targets of natural products without chemical modification. Nat Prod Rep 2016;33: 719-730
[30] Jafari R, Almqvist H, Axelsson H, Ignatushchenko M, Lundback T, Nordlund P, et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc 2014;9: 2100-2122
[31] Chen M, Zhang Y, Yu VC, Chong YS, Yoshioka T, Ge R. Isthmin targets cell-surface GRP78 and triggers apoptosis via induction of mitochondrial dysfunction. Cell Death Differ 2014;21: 797-810
[32] Wang SH, Lee AC, Chen IJ, Chang NC, Wu HC, Yu HM, et al. Structure-based optimization of GRP78-binding peptides that enhances efficacy in cancer imaging and therapy. Biomaterials 2016;94: 31-44
[33] Farshbaf M, Khosroushahi AY, Mojarad-Jabali S, Zarebkohan A, Valizadeh H, Walker PR. Cell surface GRP78: an emerging imaging marker and therapeutic target for cancer. J Control Release 2020;328: 932-941
[34] Bailly C, Waring MJ. Pharmacological effectors of GRP78 chaperone in cancers. Biochem Pharmacol 2019;163: 269-278
[35] Nicolai A, Delarue P, Senet P. Decipher the mechanisms of protein conformational changes induced by nucleotide binding through free-energy landscape analysis: ATP binding to Hsp70. PLoS Comput Biol 2013;9: e1003379
[36] Tsai YL, Zhang Y, Tseng CC, Stanciauskas R, Pinaud F, Lee AS. Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface. J Biol Chem 2015;290: 8049-8064
[37] Tashima, T. Effective cancer therapy based on selective drug delivery into cells across their membrane using receptor-mediated endocytosis. Bioorg Med Chem Lett 2018;28: 3015-3024
[38] Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer 2020;11: 2008-2021
[39] Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-3499
[40] Ge R, Kao C. Cell surface GRP78 as a death receptor and an anticancer drug target. Cancers 2019;11: 1787
[41] Rasche L, Duell J, Morgner C, Chatterjee M, Hensel F, Rosenwald A, et al. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. PLoS One 2013;8: e63414
[42] Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003;278: 20915-20924
[43] Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006;66: 9260-9269
[44] Martin S, Lamb HK, Brady C, Lefkove B, Bonner MY, Thompson P, et al. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br J Cancer 2013;109: 433-443
[45] Zhang X, Chen J, Cheng C, Li P, Cai F, Xu H, et al. Aspirin potentiates celecoxib-induced growth inhibition and apoptosis in human non-small cell lung cancer by targeting GRP78 activity. Ther Adv Med Oncol 2020;12: 1758835920947976
[46] Tseng CC, Zhang P, Lee AS. The COOH-terminal proline-rich region of GRP78 is a key regulator of its cell surface expression and viability of tamoxifen-resistant breast cancer cells. Neoplasia 2019;21: 837-848
[47] Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 2014;1845: 136-154
[48] Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal 2020;18: 33
[49] Ramirez de Arellano A, Lopez-Pulido EI, Martinez-Neri PA, Estrada Chavez C, Gonzalez Lucano R, Fafutis-Morris M, et al. STAT3 activation is required for the antiapoptotic effects of prolactin in cervical cancer cells. Cancer Cell Int 2015;15: 83
[50] Yao X, Liu H, Zhang X, Zhang L, Li X, Wang C. et al. Cell surface GRP78 accelerated breast cancer cell proliferation and migration by activating STAT3. PLoS One 2015;10: e0125634
[51] Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep 2019;52: 415-423
[52] Tsai YL, Zhang Y, Tseng CC, Stanciauskas R, Pinaud F, Lee AS. Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface. J Biol Chem 2015;290: 8049-8064
[53] Lu L, Dong J, Wang L, Xia Q, Zhang D, Kim H, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene 2018;37: 5292-5304
[54] Kasiappan R, Jutooru I, Karki K, Hedrick E, Safe S. Benzyl isothiocyanate (BITC) induces reactive oxygen species-dependent repression of STAT3 protein by down-regulation of specificity proteins in pancreatic cancer. J Biol Chem 2016;291: 27122-27133
Similar articles: